Undisclosed GPCR-targeting programs
Broad range of cancers including breast cancer, lung cancer
Key Facts
About Radionetics Oncology
Radionetics Oncology is a private, San Diego-based biotech founded in 2021, focused on expanding the application of radiopharmaceuticals in solid tumors through its innovative GPCR-targeting platform. The company has secured a significant strategic agreement with Eli Lilly, including a $140 million upfront payment and a potential $1 billion acquisition option, validating its technology and providing substantial non-dilutive capital. With a deep leadership team experienced in GPCR biology and drug development, Radionetics is advancing a preclinical pipeline targeting cancers with high unmet need, such as breast and lung cancer, positioning itself at the forefront of the next wave in precision oncology therapeutics.
View full company profile